Actuate Therapeutics Inc

NASDAQ:ACTU

Biotechnology

Healthcare
$2.09 +2.96%

+$0.06 today

Market cap
$50.01M
Beta
0.53
P/E (TTM)
-2.3
EPS (TTM)
-$0.92
52W Low $1.58High $9.22

Volume 0.03M

Average 0.16M

ACTU Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Actuate Therapeutics IncNASDAQ: ACTU

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses grows, but more slowly than its trailing trend

Q1 FY2026 other income / expenses of $80.21K rose 65.2% year over year, behind the +119.3% change in trailing-twelve-month other income / expenses. Sequentially, it fell 40.4% from the prior quarter. Over 3 fiscal years it compounded at +78.0% a year.

Context

  • Other income / expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +65.2% toward the trailing-twelve-month pace of +119.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$80.21K-40.4% QoQ
Last fiscal yearDec 2025
$267.46K+112.6% YoY
LTMMar 2026
$299.11K+119.3% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+65.2%——
1 year+112.6%——
3-year CAGR+78.0%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
267.46K USD
Year-over-year change
+112.6%
3-year CAGR
+78.0%

Other Income / Expenses vs competitors

How ACTU compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +119.3% is the highest of 9, against a peer median of -43.6%.
  • Over three fiscal years its annual growth of +78.0% compares with a peer median of +11.3%.
ACTU Competitors
Other Income / Expenses for ACTU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MCRBSeres Therapeutics, Inc.LTM Mar 2026$40.74M USD-24.4%—3552.1%
NKTXNkarta, Inc.LTM Mar 2026$16.38M USD-21.0%+49.6%—
ALECAlector, Inc.LTM Mar 2026$11.31M USD-50.1%-26.8%61.4%
PEPGPepGen Inc.LTM Mar 2026$4.08M USD-37.0%+11.3%—
SPROSpero Therapeutics, Inc.LTM Mar 2026$1.99M USD-54.2%—3.6%
ACTUActuate Therapeutics IncLTM Mar 2026$299.11K USD+119.3%+78.0%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$2.61M USD+55.1%——
MOLNMolecular Partners AGLTM Mar 2026-CHF 6.37M CHF-427.8%——
VORVor Biopharma Inc.LTM Mar 2026-$509.57M USD-14437.9%——
Peer median (excluding ACTU) —-43.6%+11.3%61.4%

Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development16.39M21.71M18.68M10.29M
Selling, General & Admin3.82M3.27M6.48M12.2M
Operating Expenses20.21M24.97M25.16M22.5M
Depreciation & Amortization63.61K272.85K2.14M0
EBITDA(20.08M)(24.43M)(25.16M)(22.21M)
EBITDA Margin————
Operating Income(20.21M)(24.97M)(25.16M)(22.5M)
Operating Margin————
Interest Income27.03K352.67K222.29K287.71K
Interest Expense16.2K43.64K(18.72K)20.25K
Other Income / Expenses47.41K229.21K(2.12M)267.46K
Income Before Tax(20.16M)(24.74M)(27.28M)(22.23M)
Pre-Tax Margin————
Income Tax Expense008000
Net Income(20.16M)(24.74M)(27.29M)(22.23M)
Net Margin————
EPS (Basic)(1.34)(1.65)(3.26)(1.06)
EPS (Diluted)(1.34)(1.65)(3.26)(1.06)
Weighted Avg Shares15.03M15.03M19.51M21.02M
Weighted Avg Shares (Diluted)15.03M15.03M19.51M21.02M

Actuate Therapeutics Inc

NASDAQ:ACTU

Intrinsic Alpha fair value

Locked

Current Price

$2.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.